Advertisement

Retinoid Therapy

A review of clinical and laboratory research

  • Editors
  • W. J. Cunliffe
  • A. J. Miller

Table of contents

  1. Front Matter
    Pages i-xvi
  2. The Development of Retinoids in Dermatology

    1. W. Bollag, J.-M. Geiger
      Pages 1-7
  3. Etretinate — Clinical and Laboratory

    1. Front Matter
      Pages 9-9
    2. M. Hazell, R. Marks
      Pages 25-37
    3. J. G. van der Schroeff, H. J. van der Rhee
      Pages 39-43
    4. P. Fritsch
      Pages 45-54
    5. C. M. Lawrence, J. Marks, S. Parker, P. R. Coburn, S. Shuster
      Pages 55-60
    6. S. M. Burge, J. D. Wilkinson
      Pages 61-62
    7. D. J. Atherton, R. S. Wells
      Pages 63-71
    8. Ch. Grupper, B. Berretti
      Pages 73-81
    9. N. Hammersley, M. M. Ferguson, N. B. Simpson
      Pages 83-88
  4. Etretinate — Mechanism of Action

    1. Front Matter
      Pages 89-89
    2. R. Marks, A. D. Pearse, T. Hashimoto, S. Barton
      Pages 91-99
    3. D. Tsambaos, B. Zimmermann, C. E. Orfanos
      Pages 119-133
    4. A. Vahlquist, O. Rollman
      Pages 135-143
    5. M. J. Kamiński, A. Szmurlo, S. Majewski, S. Jablońska, M. Pawińska
      Pages 145-151
    6. A. Langner, M. Fraczykowska, S. Jablońska, J. Szymańczyk, T. Chorzelski
      Pages 153-158
  5. Special Examinations with the Retinoids

  6. Retinoids and Neoplasia

    1. Front Matter
      Pages 179-179
    2. G. Mathé, G. Santelli, J. Gouveia, G. Lemaigre, J. L. Misset, F. Gros et al.
      Pages 181-186
    3. B. Berretti, Ch. Grupper
      Pages 187-194
    4. T. Kingston, R. Marks
      Pages 195-199
  7. Isotretinoin — Clinical and Laboratory

    1. Front Matter
      Pages 201-201
    2. D. H. Jones, W. J. Cunliffe, K. King, A. J. Miller
      Pages 203-213
    3. A. R. Shalita
      Pages 215-221
    4. W. J. Cunningham
      Pages 223-228
  8. Isotretinoin — Duration of Remission of Acne

    1. Front Matter
      Pages 229-229
    2. H. Wokalek, R. Hennes, H. Schell, H. J. Vogt
      Pages 231-239
    3. D. H. Jones, W. J. Cunliffe
      Pages 241-251
  9. Isotretinoin — Mechanism of Action

    1. Front Matter
      Pages 253-253
    2. W. J. Cunliffe, D. H. Jones, K. T. Holland, S. Millard, H. Al-Baghdadi
      Pages 255-266
    3. M. Orme, D. J. Back, W. J. Cunliffe, D. H. Jones, W. L. Allen, J. Tjia
      Pages 277-283
  10. Comparisons of Isotretinoin with other Drugs in the Treatment of Severe Acne

    1. Front Matter
      Pages 285-285
    2. D. H. Jones, W. J. Cunliffe, A. Löffler
      Pages 293-301
    3. A. Mack, H. Wokalek, B. Maas, R. Cörlin
      Pages 303-311
  11. Other Uses of Isotretinoin

    1. Front Matter
      Pages 313-313
    2. R. A. Fulton, D. C. Dick, R. M. Mackie
      Pages 315-319
    3. W. J. Cunningham
      Pages 321-325
  12. New Aspects of Retinoid Therapy

  13. Back Matter
    Pages 365-369

About this book

Introduction

The impact of the retinoids in clinical practice has primarily been in dermatology. When Dr Werner Bollag began his basic research and screening programme in the early 1960's, the expectation was that the retinoids would have a major impact on oncology. However, the laboratory and clinical experiences of Bollag and his colleagues in Switzerland, Stuttgen and Orfanos in Germany, led to publications on both etretinates (Tigason) and isotretinoin (Roaccutane) in the years between 1972 and 1976 in the field of dermatology. In fact the first symposium on retinoid research held in Berlin in 1981 was almost entirely dermatological. A year later a retinoid workshop in Iowa was designed to provide a forum for dermatolog­ ists from the USA involved in specific protocols investigating oral retinoids. In the UK, research into the retinoids began rather later than in Continental Europe or in the USA, although Tigason was first marketed here. It was felt in late 1982 that as many dermatologists had relatively little experience with these compounds it would be appropriate to hold an International Symposium on retinoid therapy in the UK. Thus on 16-18 May 1983 in London, 37 speakers from 11 countries addressed an audience of 300, aminly UK, dermatologists. The scientific organizing committee consisted of but two persons Dr William Cunliffe of Leeds General Infirmary, representing the European Society of Dermatolo­ gical Research, and myself from Roche Clinical Research. The Symposium was held under the auspices of the ESDR and of Roche Products Limited.

Keywords

therapy

Bibliographic information

  • DOI https://doi.org/10.1007/978-94-011-6349-1
  • Copyright Information Springer Science+Business Media B.V. 1984
  • Publisher Name Springer, Dordrecht
  • eBook Packages Springer Book Archive
  • Print ISBN 978-94-011-6351-4
  • Online ISBN 978-94-011-6349-1
  • Buy this book on publisher's site